• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴基斯坦精神分裂症样本中的差异治疗反应:与社会人口统计学参数、药物成瘾、治疗态度及抗精神病药物的相关性

Differential Treatment Responses in Pakistani Schizophrenia Samples: Correlation with Sociodemographic Parameters, Drug Addiction, Attitude to the Treatment and Antipsychotic Agents.

作者信息

Habiba Umme, Malik Aafia, Raja Ghazala Kaukab, Memon Muhammad Raza, Nizami Asad Tameezud Din, Ishaq Rafaqat, Ilyas Muhammad, Valadi Hadi, Nawaz Muhammad, Shaiq Pakeeza Arzoo

机构信息

University Institute of Biochemistry and Biotechnology, Pir Mehr Ali Shah, Arid Agriculture University Rawalpindi, Shamsabad, Rawalpindi 46300, Pakistan.

Department of Psychiatry, Jinnah Hospital Usmani Road, Quaid-i-Azam Campus, Lahore 54550, Pakistan.

出版信息

Brain Sci. 2023 Feb 26;13(3):407. doi: 10.3390/brainsci13030407.

DOI:10.3390/brainsci13030407
PMID:36979217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10046393/
Abstract

Schizophrenia patients demonstrate variations in response to different therapies that are currently being used for the treatment of disorders, such as augmentation therapy (ECT or mood stabilizer) and combination therapy (with antipsychotics). These therapies are also used to treat schizophrenia patients in Pakistan; however, patients show poor overall response. Therefore, this study was conducted to investigate the association between the patients' response to treatment and the use of antipsychotic agents, with variability in overall response, within different groups of patients. We conducted a retrospective study that included schizophrenia subjects (N = 200) belonging to different age groups, ethnicities, and regions from different outpatient and inpatient departments in psychiatric institutes located in different cities of Pakistan. These patients were assessed for their response to treatment therapies and categorized into four groups (non-responders (N-R), slow response (S-R), patients with relapse, and completely recovered patients (C-R)) according to their responses. The final analysis included 200 subjects, of which 73.5% were males. Mean age was 34 ± 10 years. Percentage of N-R was 5%, S-R was 42%, patients with relapse were 24%, and C-R was 1.5%. The generalized linear regression model shows a significant association between medication response and age ( = 0.0231), age of onset ( = 0.0086), gender ( = 0.005), and marital status ( = 0.00169). Variability within the medication responses was a result of the treatment regime followed. Antipsychotic agents were significantly associated with the treatment response ( = 0.00258, F = 4.981) of the patients. Significant variation was also observed in the treatment response ( = 0.00128) of the patients that were given augmentation therapy as well as combination therapy. The data suggests proper monitoring of patients' behavior in response to treatment therapies to implement tailored interventions. Despite several genetic studies supporting the heritability of schizophrenia, an insignificant association between characteristic features and family history might have been due to the limited sample size, suggesting collaborative work with massive sample sizes.

摘要

精神分裂症患者对目前用于治疗精神障碍的不同疗法(如强化治疗(电休克治疗或心境稳定剂)和联合治疗(与抗精神病药物联用))的反应存在差异。这些疗法也用于治疗巴基斯坦的精神分裂症患者;然而,患者的总体反应较差。因此,本研究旨在调查患者对治疗的反应与抗精神病药物使用之间的关联,以及不同患者群体中总体反应的变异性。我们进行了一项回顾性研究,纳入了来自巴基斯坦不同城市精神病院不同门诊和住院科室、不同年龄组、种族和地区的精神分裂症患者(N = 200)。根据这些患者对治疗疗法的反应对他们进行评估,并分为四组(无反应者(N - R)、反应缓慢者(S - R)、复发患者和完全康复患者(C - R))。最终分析包括200名受试者,其中73.5%为男性。平均年龄为34±10岁。无反应者的比例为5%,反应缓慢者为42%,复发患者为24%,完全康复患者为1.5%。广义线性回归模型显示药物反应与年龄( = 0.0231)、发病年龄( = 0.0086)、性别( = 0.005)和婚姻状况( = 0.00169)之间存在显著关联。药物反应的变异性是所遵循治疗方案的结果。抗精神病药物与患者的治疗反应( = 0.00258,F = 4.981)显著相关。在接受强化治疗和联合治疗的患者的治疗反应( = 0.00128)中也观察到了显著差异。数据表明,应适当监测患者对治疗疗法的反应行为,以实施针对性干预。尽管有几项基因研究支持精神分裂症的遗传性,但特征与家族史之间无显著关联可能是由于样本量有限,这表明需要开展大规模样本量的合作研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/235f35823b71/brainsci-13-00407-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/69a39eddbc7b/brainsci-13-00407-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/7893fb22930b/brainsci-13-00407-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/39ba83b6a1a5/brainsci-13-00407-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/c5a6983dca9f/brainsci-13-00407-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/cd80d3922697/brainsci-13-00407-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/235f35823b71/brainsci-13-00407-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/69a39eddbc7b/brainsci-13-00407-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/7893fb22930b/brainsci-13-00407-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/39ba83b6a1a5/brainsci-13-00407-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/c5a6983dca9f/brainsci-13-00407-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/cd80d3922697/brainsci-13-00407-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d0/10046393/235f35823b71/brainsci-13-00407-g006.jpg

相似文献

1
Differential Treatment Responses in Pakistani Schizophrenia Samples: Correlation with Sociodemographic Parameters, Drug Addiction, Attitude to the Treatment and Antipsychotic Agents.巴基斯坦精神分裂症样本中的差异治疗反应:与社会人口统计学参数、药物成瘾、治疗态度及抗精神病药物的相关性
Brain Sci. 2023 Feb 26;13(3):407. doi: 10.3390/brainsci13030407.
2
Using antipsychotic agents in older patients.在老年患者中使用抗精神病药物。
J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4.
3
ECT augmentation of antipsychotics in severely ill schizophrenia: a naturalistic, observational study.抗精神病药物联合电休克治疗重症精神分裂症:一项自然主义的观察性研究。
Int J Psychiatry Clin Pract. 2020 Nov;24(4):392-397. doi: 10.1080/13651501.2020.1777313. Epub 2020 Jun 15.
4
[Antipsychotics in bipolar disorders].[双相情感障碍中的抗精神病药物]
Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5.
5
Treatment adherence and insight in schizophrenia.精神分裂症的治疗依从性与自知力
Psychiatr Hung. 2015;30(1):18-26.
6
[Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].[在查尔斯·佩伦斯精神病院(波尔多)使用非典型抗精神病药物:对氨磺必利、氯氮平、奥氮平和利培酮处方实践的分析]
Encephale. 2002 Jul-Aug;28(4):329-42.
7
[Therapeutic benefit of a registered psychoeducation program on treatment adherence, objective and subjective quality of life: French pilot study for schizophrenia].[一项注册心理教育项目对治疗依从性、客观和主观生活质量的治疗益处:精神分裂症的法国试点研究]
Encephale. 2017 May;43(3):235-240. doi: 10.1016/j.encep.2015.12.028. Epub 2016 Sep 19.
8
Electroconvulsive therapy for schizophrenia.精神分裂症的电休克治疗
Cochrane Database Syst Rev. 2005 Apr 18(2):CD000076. doi: 10.1002/14651858.CD000076.pub2.
9
Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.抗精神病药物与心理干预及两者联合用于首发精神病青少年(MAPS):一项多中心、三臂、随机对照试验性及可行性研究
Lancet Psychiatry. 2020 Sep;7(9):788-800. doi: 10.1016/S2215-0366(20)30248-0. Epub 2020 Jul 7.
10
Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.一项全基因组关联研究:与精神分裂症患者抗精神病药物治疗反应相关的五个新基因座。
Lancet Psychiatry. 2018 Apr;5(4):327-338. doi: 10.1016/S2215-0366(18)30049-X. Epub 2018 Mar 1.

本文引用的文献

1
The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia.首发未用药精神分裂症患者认知缺陷与临床特征之间的关联
Front Psychiatry. 2021 Feb 25;12:638773. doi: 10.3389/fpsyt.2021.638773. eCollection 2021.
2
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research.难治性精神分裂症的神经生物学:抗精神病药物耐药性的途径及未来研究路线图。
NPJ Schizophr. 2020 Jan 7;6(1):1. doi: 10.1038/s41537-019-0090-z.
3
Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View.
难治性精神分裂症的临床病程、神经生物学及治疗方法。迈向综合观点。
Front Psychiatry. 2019 Sep 3;10:601. doi: 10.3389/fpsyt.2019.00601. eCollection 2019.
4
Electroconvulsive Therapy and Schizophrenia: A Systematic Review.电休克治疗与精神分裂症:一项系统综述
Mol Neuropsychiatry. 2019 Apr;5(2):75-83. doi: 10.1159/000497376. Epub 2019 Apr 2.
5
Antipsychotic drugs: atypical advantages and typical disadvantages.抗精神病药物:非典型优势与典型劣势。
Ir J Psychol Med. 2003 Mar;20(1):24-27. doi: 10.1017/S0790966700007497.
6
Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.耐药性并非徒劳无益:治疗抵抗性精神分裂症——概述、评估和治疗。
Expert Opin Pharmacother. 2019 Jan;20(1):11-24. doi: 10.1080/14656566.2018.1543409. Epub 2018 Nov 8.
7
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.抗精神病药物治疗精神分裂症的急性疗效:近期荟萃分析综述
Ther Adv Psychopharmacol. 2018 Oct 8;8(11):303-318. doi: 10.1177/2045125318781475. eCollection 2018 Nov.
8
Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers.评价利用注射局部护理中心的患者的患者支持计划和对长效注射用阿立哌唑的依从性。
Curr Med Res Opin. 2019 Jan;35(1):97-103. doi: 10.1080/03007995.2018.1536651. Epub 2018 Nov 5.
9
Management of common adverse effects of antipsychotic medications.抗精神病药物常见不良反应的管理。
World Psychiatry. 2018 Oct;17(3):341-356. doi: 10.1002/wps.20567.
10
Cognitive Behavioural Therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis.精神分裂症的认知行为疗法 - 功能、痛苦和生活质量的结果:荟萃分析。
BMC Psychol. 2018 Jul 17;6(1):32. doi: 10.1186/s40359-018-0243-2.